Elotuzumab in Combination with Pomalidomide and Corticosteroids for Relapsed or Refractory Multiple Myeloma

被引：0
|
作者：
Sidiqi, Hasib [1 ]
McGregor, Scott [2 ]
Baker, Ross [2 ]
Carnley, Ben [2 ]
Radeski, Dejan [1 ]
Barraclough, Allison [1 ]
Augustson, Bradley [1 ]
机构：
[1] Sir Charles Gairdner Hosp, Perth, WA, Australia
[2] Perth Blood Inst, Perth, Australia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷 / 01期
关键词：
D O I：
10.1016/j.clml.2017.03.151
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS-149
引用
收藏
页码：E83 / E84
页数：2
相关论文
共 50 条
  • [41] Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)
    Chen, Christine I.
    Bahlis, Nizar J.
    Gasparetto, Cristina
    Tuchman, Sascha A.
    Lipe, Brea
    Baljevic, Muhamed
    Kotb, Rami
    Sutherland, Heather J.
    Bensinger, William I.
    Sebag, Michael
    LeBlanc, Richard
    Venner, Christopher P.
    Schiller, Gary J.
    Lentzsch, Suzanne
    Callander, Natalie S.
    Rossi, Adriana C.
    Sheehan, Heidi
    Van Domelen, Dane
    Kazuharu, Kai
    Wang, Hongwei
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    White, Darrell J.
    BLOOD, 2020, 136
  • [42] A Phase 3 randomized, open-label trial of selinexor, pomalidomide, and dexamethasone versus elotuzumab, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma
    Weisel, Katja
    Bentur, Ohad
    Van Domelen, Dane
    Boccadoro, Mario
    Sonneveld, Pieter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S216 - S217
  • [43] ELOQUENT-3 Trial: Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma Final Overall Survival Analysis
    Raab, Marc-Steffen
    Dimopoulos, Meletios
    Dytfeld, Dominik
    Grosicki, Sebastian
    Moreau, Philippe
    Takezako, Naoki
    Hori, Mitsuo
    Leleu, Xavier
    Leblanc, Richard
    Suzuki, Kenshi
    Richardson, Paul G.
    Mckiver, Mihaela Popa
    Jou, Ying-Ming
    Yao, David
    Das, Prianka
    San-Miguel, Jesus
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 174 - 174
  • [44] A Clinician's Perspective of Elotuzumab in the Treatment of Relapsed or Refractory Multiple Myeloma
    Richardson, Paul G.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05)
  • [45] Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting
    Ailawadhi, Sikander
    Parrondo, Ricardo D.
    Laplant, Betsy
    Alegria, Victoria R.
    Elliott, Jamie B.
    Sher, Taimur
    Paulus, Aneel
    Chapin, Dustin
    Heslop, Keisha
    Chanan-Khan, Asher
    Roy, Vivek
    BLOOD, 2022, 140 : 4450 - 4451
  • [46] Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma
    Parrondo, Ricardo D.
    Laplant, Betsy R.
    Elliott, Jamie
    Fernandez, Andre
    Flott, Caitlin J.
    Arrington, Diedre
    Chapin, Dustin
    Brown, Jade
    Das, Saurav
    Roy, Vivek
    Chanan-Khan, Asher A.
    Ailawadhi, Sikander
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [47] Single-Arm, Phase 2 Study of Elotuzumab in Combination With Pomalidomide and Dexamethasone in Patients With Multiple Myeloma Who Are Relapsed/Refractory to Lenalidomide: Initial Safety Data
    Jagannath, Sundar
    Berdeja, Jesus
    Rifkin, Robert
    Cole, Craig
    Thompson, Michael A.
    Ricafort, Rosanna J.
    Scofield, Amanda
    Mohamed, Hesham
    Sy, Oumar
    Vij, Ravi
    Bensinger, William
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S330 - S331
  • [48] Single-Arm, Phase 2 Study of Elotuzumab in Combination With Pomalidomide and Dexamethasone in Patients With Multiple Myeloma Who Are Relapsed/Refractory to Lenalidomide: Initial Safety Data
    Jagannath, Sundar
    Berdeja, Jesus
    Rifkin, Robert
    Cole, Craig
    Thompson, Michael A.
    Ricafort, Rosanna J.
    Scofield, Amanda
    Mohamed, Hesham
    Sy, Oumar
    Vij, Ravi
    Bensinger, William
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E127 - E127
  • [49] Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma
    Hussain, M. Junaid
    Robinson, Myra M.
    Hamadeh, Issam
    Arnall, Justin
    Bhutani, Manisha
    Atrash, Shebli
    Friend, Reed
    Pineda-Roman, Mauricio
    Symanowski, James T.
    Usmani, Saad Z.
    Voorhees, Peter M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (01) : 140 - 144
  • [50] Treatment of multiple Myeloma with Elotuzumab plus Pomalidomide and Dexamethasone
    Rasche, L.
    Einsele, H.
    Nitschmann, S.
    INTERNIST, 2019, 60 (06): : 658 - 660
12345